Feuerstein questions Stemline's use of message board posts

|About: Stemline Therapeutics (STML)|By:, SA News Editor

Shares of Stemline Therapeutics (STML) are off 4% in premarket trading in the face of a rather negative article by TheStreet's Adam Feuerstein.

Feuerstein discusses the company's use of posts from a message board (hosted by the Leukemia and Lymphoma Society) in its investor slide deck.

The article questions the appropriateness of leaving out certain passages of the posts when using them in the investor presentation.

Feuerstein also says "a donor lymphocyte infusion" may have contributed to the complete remission of one patient being treated with SL-401, a possibility the company acknowledged as "within the realm of possibility."

For more on SL-401, see here.